{"gene":"RNASE3","run_date":"2026-06-10T06:43:37","timeline":{"discoveries":[{"year":1986,"finding":"ECP (RNASE3) possesses ribonuclease activity; purified ECP resolved into subfractions by ion exchange chromatography all showed RNase activity, though ~125-fold lower than EPX/EDN. ECP may exert cytotoxic effects by degrading mRNA after internalization.","method":"Ion exchange chromatography of purified ECP, RNase activity assay","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct enzymatic assay on purified protein, replicated across multiple subfractions, consistent with subsequent substrate-preference studies","pmids":["3768000"],"is_preprint":false},{"year":1986,"finding":"ECP and EPX dose-dependently suppressed lymphocyte proliferation (PHA-blasts and MLR-blasts) in vitro; the effect was irreversible and not due to cytotoxic cell damage, suggesting a regulatory immunosuppressive role for eosinophil-derived proteins.","method":"In vitro lymphocyte proliferation assay with purified ECP/EPX, 3H-thymidine incorporation","journal":"Immunobiology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct in vitro functional assay on purified protein, single lab, no mechanistic pathway placement beyond the observed phenotype","pmids":["2940166"],"is_preprint":false},{"year":1991,"finding":"ECP's RNase activity shows substrate preference for single-stranded RNA (poly(U) > poly(C) >> poly(A)); double-stranded substrates and defined dinucleoside phosphate substrates showed negligible hydrolysis, linking ECP ribonucleolytic activity to 'non-secretory' liver-type enzymes rather than pancreatic-type RNases.","method":"In vitro RNase activity assay with synthetic polyribonucleotide substrates, dinucleoside phosphates, and cyclic phosphates","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct substrate-preference enzymatic assay with multiple substrates on purified protein, single lab but multiple orthogonal substrate tests","pmids":["1715291"],"is_preprint":false},{"year":1997,"finding":"Optimal expression of the ECP (RNS3) gene is mediated by an intronic enhancer element containing an NFAT-1 consensus binding sequence (5'-GGAGAG-3'); nuclear proteins from HL-60 cells bind this site and disruption reduces reporter gene activity to background. A single nucleotide difference from the EDN intronic NFAT-1 site further enhanced ECP reporter activity. No supershift was detected with anti-NFAT-1 antiserum, suggesting a protein other than NFAT-1 may act at this site.","method":"Reporter gene assay, gel shift (EMSA) with nuclear proteins from HL-60 cells, site-directed mutagenesis of consensus sequence","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay plus EMSA with mutagenesis, single lab; identity of binding protein unresolved (negative supershift result for NFAT-1)","pmids":["8999843"],"is_preprint":false},{"year":2001,"finding":"SNARE proteins (VAMP-2, syntaxin 4, SNAP-23/SNAP-25) are present in human eosinophils and are required for regulated ECP exocytosis; tetanus toxin pretreatment, which cleaved VAMP-2, significantly inhibited both IgE receptor- and phorbol ester-mediated ECP release from streptolysin-O-permeabilized eosinophils.","method":"Immunoblotting, subcellular fractionation, immunocytochemistry, RT-PCR, tetanus toxin cleavage of VAMP-2, exocytosis assay in permeabilized eosinophils","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (fractionation, immunocytochemistry, functional inhibition via toxin), single lab; mechanistic pathway placement clear","pmids":["11263991"],"is_preprint":false},{"year":2002,"finding":"Human RNase 3 (ECP) is extraordinarily stable compared with other human pancreatic-type RNases (RNases 1–5) and bovine RNase A, with a ΔΔG of >25 kJ/mol in guanidinium chloride-induced unfolding experiments; this exceptional stability may enable ECP to accumulate in the cytosol after endocytosis to levels exceeding those of the RNase inhibitor, contributing to its unique cytotoxic properties.","method":"Guanidinium chloride-induced denaturation, two-state unfolding analysis, comparison across five human RNases and RNase A","journal":"Journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — rigorous biophysical assay, but single lab and mechanistic link to cytotoxicity is inferential from stability data","pmids":["12417023"],"is_preprint":false},{"year":2009,"finding":"ECP (RNase 3) triggers vesicle aggregation as the primary membrane interaction event, whereas RNase 7 induces leakage before aggregation; RNase 3 membrane interaction involves aggregation of phospholipid vesicles followed by leakage, distinct from RNase 7's mechanism, as shown by confocal microscopy with GUVs, liposome content-release assay, electron microscopy of lipid/protein aggregates, and FTIR of secondary structure in lipid microenvironment.","method":"Phospholipid vesicle model membranes, confocal microscopy (giant unilamellar vesicles), liposome content-release (leakage) assay, transmission electron microscopy, FTIR spectroscopy","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal biophysical methods (confocal, TEM, FTIR, leakage assay), single lab, defines specific membrane interaction mechanism","pmids":["19366593"],"is_preprint":false},{"year":2009,"finding":"ECP secretion from activated eosinophils involves post-translational processing: unstimulated eosinophils contain 10 major ECP variants (16.1–17.7 kDa); particle stimulation selectively secretes 16.1 and 16.3 kDa variants (the cytotoxic species), while cytokine stimulation produces a different secretion profile. Modifications of secreted ECP are partly explained by differences in N-linked glycosylations.","method":"SELDI-TOF mass spectrometry, affinity capture assay, fluoroenzyme immunoassay, eosinophil stimulation with particles/cytokines","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — SELDI-TOF with functional stimulation conditions, single lab, two orthogonal analytical methods; glycosylation differences identified but full characterization incomplete","pmids":["19692640"],"is_preprint":false},{"year":2009,"finding":"The arg97thr amino acid substitution encoded by the ECP 434(G>C) polymorphism dramatically abolishes cytotoxic capacity of native ECP toward NCI-H69 small-cell lung cancer cells, but does not affect RNase activity and only minimally affects fibroblast-mediated collagen gel contraction, demonstrating dissociation between different biological activities of ECP.","method":"Native ECP(97arg) and ECP(97thr) variants extracted from blood donors, fluorometric microculture cytotoxicity assay, RNase activity assay, fibroblast collagen gel contraction assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — first-ever native protein variant comparison with three orthogonal functional assays (cytotoxicity, RNase, gel contraction), single lab but multiple rigorous endpoints","pmids":["19542456"],"is_preprint":false},{"year":2011,"finding":"ECP heparin-binding affinity is dependent on its RNase catalytic site: heparin and other negatively charged glycosaminoglycans (GAGs) block ECP enzymatic activity, and molecular modeling identified catalytic and substrate-binding site residues as contributors to GAG interaction, explaining ECP binding to the eukaryote glycocalyx and bacteria cell wall carbohydrates.","method":"Enzymatic activity inhibition assay with heparin/GAGs, molecular modeling","journal":"Journal of molecular recognition","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct enzymatic inhibition assay plus computational modeling, single lab; mechanistic link to antimicrobial action is partially inferential","pmids":["20213669"],"is_preprint":false},{"year":2001,"finding":"ECP degrades myofibrillar proteins (myosin heavy chain, α-actinin) and membrane-associated cytoskeletal proteins (dystrophin, spectrin) in vitro in a dose-dependent, pH 7.0-optimal manner; soluble sarcoplasmic proteins were not degraded. Degradation was not inhibited by heparin or protease inhibitors (leupeptin, E-64, pepstatin A).","method":"In vitro incubation of muscle protein fractions with purified ECP, SDS-PAGE, immunoblotting, quantitative MHC degradation assay","journal":"Muscle & nerve","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct in vitro proteolytic assay on purified protein with defined substrates and inhibitor controls, single lab","pmids":["11745972"],"is_preprint":false},{"year":2012,"finding":"ECP is implicated in the breakdown of free soluble RAGE (sRAGE) in sinonasal tissue; ex vivo human sinonasal tissue stimulation with ECP reduced sRAGE levels, while S. aureus induced sRAGE release from tissue.","method":"Ex vivo sinonasal tissue stimulation assay, quantitative protein measurement (ELISA/immunoassay) for sRAGE, mRAGE, ECP, IL-5","journal":"The Journal of allergy and clinical immunology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single ex vivo stimulation assay, single lab; mechanism of sRAGE breakdown not characterized at molecular level","pmids":["22460069"],"is_preprint":false},{"year":2016,"finding":"An ECP-derived peptide (RN3(5-17P22-36)) achieves biofilm eradication of Pseudomonas aeruginosa through combined LPS-binding, bacterial cell agglutination, and membrane destabilization activities; biofilm eradication by the parental ECP protein is not dependent on RNase catalytic activity, as demonstrated with an active site-defective mutant.","method":"Active site-defective mutant biofilm eradication assay, LPS-binding assay, bacterial agglutination assay, bactericidal activity assay against P. aeruginosa PAO1","journal":"Antimicrobial agents and chemotherapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — active-site mutant experiment directly dissociates RNase activity from biofilm eradication; multiple functional readouts, single lab","pmids":["27527084"],"is_preprint":false},{"year":2006,"finding":"A G→C transversion at position 562 in the 3' UTR of the ECP (RNASE3) gene is associated with significantly lower cellular ECP content in eosinophils (ECP562GC: 4.6 µg/10^6 cells; GG: 6.0 µg/10^6 cells; CC: 3.2 µg/10^6 cells), suggesting this UTR polymorphism regulates ECP production/storage at a post-transcriptional level.","method":"Gene sequencing, ECP cellular content measurement by RIA in donors stratified by genotype","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct genotype-to-protein-level correlation with quantitative cellular measurement across n=163 subjects; single lab, no mechanistic dissection of UTR function","pmids":["16434694"],"is_preprint":false},{"year":1999,"finding":"EoL-1 eosinophilic leukemic cells differentiated by dibutyryl cAMP upregulate ECP mRNA expression and increase both ECP synthesis and secretion into supernatant, establishing that ECP expression is regulated at the transcriptional level during eosinophil differentiation.","method":"RT-PCR for ECP mRNA, fluorescence enzyme immunoassay for ECP protein in cells and supernatant, dbcAMP differentiation model","journal":"Immunology letters","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single cell-line model, single lab, no mechanistic dissection of transcriptional pathway","pmids":["10424438"],"is_preprint":false}],"current_model":"RNASE3 (ECP) is a highly basic eosinophil granule ribonuclease (with low but measurable RNase activity preferring single-stranded poly(U)/poly(C) substrates) that is secreted via a SNARE-dependent (VAMP-2/syntaxin-4) exocytosis mechanism with concomitant N-glycosylation-dependent processing into cytotoxic variants; its cytotoxicity is mediated primarily through membrane aggregation and destabilization rather than RNase activity, its heparin/GAG-binding affinity is mediated through the RNase catalytic site, its gene expression is regulated by an intronic NFAT-1-like enhancer element, and the arg97thr (434G>C) coding polymorphism dissociates cytotoxic activity from RNase activity without affecting the latter."},"narrative":{"mechanistic_narrative":"RNASE3 (eosinophil cationic protein, ECP) is a highly basic eosinophil granule ribonuclease whose dominant biological function is cytotoxic and antimicrobial membrane disruption rather than RNA catalysis [PMID:19366593, PMID:19542456]. It possesses measurable but weak ribonuclease activity (~125-fold lower than EDN/EPX) with a marked preference for single-stranded substrates, poly(U) > poly(C) >> poly(A), aligning it with non-secretory liver-type rather than pancreatic-type RNases [PMID:3768000, PMID:1715291]. The protein engages membranes primarily by aggregating phospholipid vesicles followed by leakage, a mechanism distinct from RNase 7 [PMID:19366593], and its cytotoxicity is genetically separable from catalysis: the arg97thr (434G>C) substitution abolishes cytotoxicity toward target cells while leaving RNase activity intact [PMID:19542456]. Likewise, biofilm eradication of Pseudomonas aeruginosa proceeds through LPS binding, bacterial agglutination, and membrane destabilization independent of the catalytic site [PMID:27527084], while heparin/glycosaminoglycan binding — which underlies engagement of the glycocalyx and bacterial cell-wall carbohydrates — is itself mediated through the RNase catalytic and substrate-binding residues [PMID:20213669]. ECP is stored in eosinophil granules and released by SNARE-dependent regulated exocytosis requiring VAMP-2 and syntaxin-4, with stimulus-selective secretion of N-glycosylation-defined cytotoxic variants [PMID:11263991, PMID:19692640]. Its expression is controlled both transcriptionally via an intronic NFAT-1-like enhancer element [PMID:8999843] and post-transcriptionally via a 3'UTR polymorphism that sets cellular ECP content [PMID:16434694].","teleology":[{"year":1986,"claim":"Established that ECP is an enzymatically active ribonuclease, framing it as a member of the RNase superfamily and raising the question of whether RNA degradation underlies its biological effects.","evidence":"Ion exchange chromatography of purified ECP with RNase activity assays across subfractions","pmids":["3768000"],"confidence":"High","gaps":["Did not determine whether RNase activity drives cytotoxicity","Activity ~125-fold lower than EDN/EPX, leaving functional relevance unclear"]},{"year":1986,"claim":"Showed ECP has an immunoregulatory dimension, irreversibly suppressing lymphocyte proliferation independent of overt cell damage.","evidence":"In vitro lymphocyte proliferation assay (PHA/MLR blasts) with purified ECP, 3H-thymidine incorporation","pmids":["2940166"],"confidence":"Medium","gaps":["No molecular pathway or receptor identified","Mechanism of irreversible suppression not defined"]},{"year":1991,"claim":"Defined the substrate preference of ECP (single-stranded poly(U)>poly(C)>>poly(A)), placing it with non-secretory liver-type rather than pancreatic-type RNases.","evidence":"In vitro RNase assays with synthetic polyribonucleotides, dinucleoside phosphates, and cyclic phosphates","pmids":["1715291"],"confidence":"High","gaps":["Physiological RNA substrate in vivo not identified","Does not connect catalysis to cellular function"]},{"year":1997,"claim":"Identified an intronic NFAT-1-like enhancer driving optimal ECP gene expression, addressing how the gene is transcriptionally controlled.","evidence":"Reporter assays, EMSA with HL-60 nuclear extracts, site-directed mutagenesis","pmids":["8999843"],"confidence":"Medium","gaps":["Identity of the binding protein unresolved (anti-NFAT-1 supershift negative)","Upstream signaling that activates the enhancer unknown"]},{"year":1999,"claim":"Linked ECP expression to eosinophil differentiation, showing transcriptional upregulation upon dbcAMP-induced maturation.","evidence":"RT-PCR and enzyme immunoassay in dbcAMP-differentiated EoL-1 leukemic cells","pmids":["10424438"],"confidence":"Low","gaps":["Single cell-line model, not validated in primary eosinophils","No transcriptional pathway dissected"]},{"year":2001,"claim":"Resolved the secretion mechanism, establishing that regulated ECP exocytosis is SNARE-dependent and requires VAMP-2.","evidence":"Immunoblotting, fractionation, immunocytochemistry, tetanus-toxin cleavage of VAMP-2, exocytosis assay in permeabilized eosinophils","pmids":["11263991"],"confidence":"High","gaps":["Full SNARE complex stoichiometry not defined","Link between stimulus type and SNARE selection unresolved"]},{"year":2001,"claim":"Demonstrated ECP proteolytic degradation of myofibrillar and membrane cytoskeletal proteins, expanding its activities beyond RNA catalysis.","evidence":"In vitro incubation of muscle protein fractions with purified ECP, SDS-PAGE, immunoblot, with protease-inhibitor controls","pmids":["11745972"],"confidence":"Medium","gaps":["Catalytic basis of proteolysis (not blocked by standard protease inhibitors) unexplained","In vivo relevance to tissue damage not established"]},{"year":2002,"claim":"Showed ECP is exceptionally thermodynamically stable, providing a biophysical rationale for cytosolic persistence above RNase inhibitor levels.","evidence":"Guanidinium chloride denaturation and two-state unfolding analysis across human RNases and RNase A","pmids":["12417023"],"confidence":"Medium","gaps":["Cytotoxicity link is inferential from stability","Cytosolic accumulation not directly measured"]},{"year":2009,"claim":"Defined the primary membrane interaction mechanism as vesicle aggregation followed by leakage, distinguishing ECP from RNase 7.","evidence":"GUV confocal microscopy, liposome content-release assay, TEM, FTIR with model membranes","pmids":["19366593"],"confidence":"High","gaps":["Membrane target specificity on living cells not defined","Structural determinants of aggregation not mapped"]},{"year":2009,"claim":"Showed stimulus-selective secretion of N-glycosylation-defined ECP variants, identifying the cytotoxic 16.1/16.3 kDa species.","evidence":"SELDI-TOF MS, affinity capture, fluoroenzyme immunoassay after particle vs cytokine stimulation","pmids":["19692640"],"confidence":"Medium","gaps":["Glycan structures only partly characterized","Enzymes generating the variants not identified"]},{"year":2009,"claim":"Genetically dissociated cytotoxicity from RNase activity, showing arg97thr abolishes cytotoxicity without affecting catalysis.","evidence":"Native ECP(97arg/97thr) variants from donors tested by cytotoxicity, RNase, and collagen gel contraction assays","pmids":["19542456"],"confidence":"High","gaps":["Structural basis of how residue 97 controls cytotoxicity unknown","Target-cell receptor/interaction not identified"]},{"year":2011,"claim":"Mapped heparin/GAG binding to the RNase catalytic site, explaining glycocalyx and bacterial cell-wall engagement.","evidence":"Enzymatic inhibition assays with heparin/GAGs plus molecular modeling","pmids":["20213669"],"confidence":"Medium","gaps":["Modeling not validated by structure of GAG complex","Antimicrobial link partly inferential"]},{"year":2012,"claim":"Implicated ECP in degradation of soluble RAGE in sinonasal tissue, suggesting a role in modulating innate immune signaling substrates.","evidence":"Ex vivo human sinonasal tissue stimulation with ECP and quantitation of sRAGE/mRAGE","pmids":["22460069"],"confidence":"Low","gaps":["Single ex vivo assay, not independently confirmed","Molecular mechanism of sRAGE breakdown uncharacterized"]},{"year":2016,"claim":"Established that antibacterial biofilm eradication is independent of RNase activity, mediated by LPS binding, agglutination, and membrane destabilization.","evidence":"Active-site-defective mutant biofilm assay, LPS-binding, agglutination, and bactericidal assays against P. aeruginosa","pmids":["27527084"],"confidence":"Medium","gaps":["Bacterial membrane target specificity not defined","Relevance of peptide derivative vs full protein in vivo unclear"]},{"year":null,"claim":"How residue 97 and N-glycosylation status structurally control the membrane-aggregation cytotoxic mechanism, and what cellular receptors or targets mediate ECP cytotoxicity and immunomodulation in vivo, remain open.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of ECP bound to membrane or target","No identified cell-surface receptor for cytotoxicity","In vivo physiological substrates undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,2]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[0,2]},{"term_id":"GO:0090729","term_label":"toxin activity","supporting_discovery_ids":[6,8]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[6,12]}],"localization":[{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[4,7]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[4,7]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,4,12]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[4,7]}],"complexes":[],"partners":["VAMP2","STX4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P12724","full_name":"Eosinophil cationic protein","aliases":["Ribonuclease 3","RNase 3"],"length_aa":160,"mass_kda":18.4,"function":"Cytotoxin and helminthotoxin with low-efficiency ribonuclease activity. Possesses a wide variety of biological activities. Exhibits antibacterial activity, including cytoplasmic membrane depolarization of preferentially Gram-negative, but also Gram-positive strains. Promotes E.coli outer membrane detachment, alteration of the overall cell shape and partial loss of cell content","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P12724/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RNASE3","classification":"Not Classified","n_dependent_lines":6,"n_total_lines":1208,"dependency_fraction":0.004966887417218543},"opencell":{"profiled":true,"resolved_as":"RAF1","ensg_id":"ENSG00000132155","cell_line_id":"CID001255","localizations":[{"compartment":"cytoplasmic","grade":3}],"interactors":[{"gene":"ARAF","stoichiometry":10.0},{"gene":"ARL8B","stoichiometry":0.2},{"gene":"FKBP5","stoichiometry":0.2},{"gene":"MAP2K1","stoichiometry":0.2},{"gene":"MAP2K2","stoichiometry":0.2},{"gene":"PHAX","stoichiometry":0.2},{"gene":"YWHAZ","stoichiometry":0.2},{"gene":"YWHAE","stoichiometry":0.2},{"gene":"YWHAB","stoichiometry":0.2},{"gene":"RBM23","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001255","total_profiled":1310},"omim":[{"mim_id":"601728","title":"PHOSPHATASE AND TENSIN HOMOLOG; PTEN","url":"https://www.omim.org/entry/601728"},{"mim_id":"600807","title":"ASTHMA, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/600807"},{"mim_id":"131410","title":"RIBONUCLEASE A FAMILY, MEMBER 2; RNASE2","url":"https://www.omim.org/entry/131410"},{"mim_id":"131398","title":"RIBONUCLEASE A FAMILY, MEMBER 3; RNASE3","url":"https://www.omim.org/entry/131398"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"bone marrow","ntpm":856.4}],"url":"https://www.proteinatlas.org/search/RNASE3"},"hgnc":{"alias_symbol":["ECP","RAF1"],"prev_symbol":["RNS3"]},"alphafold":{"accession":"P12724","domains":[{"cath_id":"3.10.130.10","chopping":"33-160","consensus_level":"high","plddt":97.1884,"start":33,"end":160}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P12724","model_url":"https://alphafold.ebi.ac.uk/files/AF-P12724-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P12724-F1-predicted_aligned_error_v6.png","plddt_mean":90.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RNASE3","jax_strain_url":"https://www.jax.org/strain/search?query=RNASE3"},"sequence":{"accession":"P12724","fasta_url":"https://rest.uniprot.org/uniprotkb/P12724.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P12724/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P12724"}},"corpus_meta":[{"pmid":"1742647","id":"PMC_1742647","title":"Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method. Establishment of normal levels in serum and turnover in vivo.","date":"1991","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1742647","citation_count":183,"is_preprint":false},{"pmid":"1571256","id":"PMC_1571256","title":"Serum eosinophil cationic protein (ECP) is a sensitive measure for disease activity in atopic dermatitis.","date":"1992","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/1571256","citation_count":136,"is_preprint":false},{"pmid":"1519835","id":"PMC_1519835","title":"Sputum ECP levels correlate with parameters of airflow obstruction.","date":"1992","source":"The American review of respiratory disease","url":"https://pubmed.ncbi.nlm.nih.gov/1519835","citation_count":105,"is_preprint":false},{"pmid":"10406252","id":"PMC_10406252","title":"Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion.","date":"1999","source":"The American journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/10406252","citation_count":97,"is_preprint":false},{"pmid":"2940166","id":"PMC_2940166","title":"Human eosinophil cationic proteins (ECP and EPX) and their suppressive effects on lymphocyte proliferation.","date":"1986","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/2940166","citation_count":88,"is_preprint":false},{"pmid":"3768000","id":"PMC_3768000","title":"The cytotoxic eosinophil cationic protein (ECP) has ribonuclease activity.","date":"1986","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/3768000","citation_count":87,"is_preprint":false},{"pmid":"16757968","id":"PMC_16757968","title":"Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression?","date":"2006","source":"Nature clinical practice. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16757968","citation_count":82,"is_preprint":false},{"pmid":"2033280","id":"PMC_2033280","title":"Detection of eosinophil cationic protein (ECP) by an enzyme-linked immunosorbent assay.","date":"1991","source":"Journal of immunological methods","url":"https://pubmed.ncbi.nlm.nih.gov/2033280","citation_count":73,"is_preprint":false},{"pmid":"7991887","id":"PMC_7991887","title":"Serum eosinophil cationic protein (ECP) in chronic asthma. Relationship to spirometry, flow-volume curves, PC20, and exacerbations.","date":"1994","source":"Respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7991887","citation_count":69,"is_preprint":false},{"pmid":"3046642","id":"PMC_3046642","title":"Extracellular deposit of the cationic proteins ECP and EPX in tissue infiltrations of eosinophils related to tissue damage.","date":"1988","source":"APMIS : acta pathologica, microbiologica, et immunologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/3046642","citation_count":64,"is_preprint":false},{"pmid":"8581845","id":"PMC_8581845","title":"Eosinophil cationic protein (ECP) and eosinophil protein X (EPX) concentrations in serum and bronchial lavage fluid in asthma. Effect of prednisolone treatment.","date":"1995","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8581845","citation_count":59,"is_preprint":false},{"pmid":"8999843","id":"PMC_8999843","title":"Intronic enhancer activity of the eosinophil-derived neurotoxin (RNS2) and eosinophil cationic protein (RNS3) genes is mediated by an NFAT-1 consensus binding sequence.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8999843","citation_count":58,"is_preprint":false},{"pmid":"9272923","id":"PMC_9272923","title":"Do sputum eosinophils and ECP relate to the severity of asthma?","date":"1997","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/9272923","citation_count":58,"is_preprint":false},{"pmid":"8187030","id":"PMC_8187030","title":"Asthma in children less than 5 years of age: eosinophils and serum levels of the eosinophil proteins ECP and EPX in relation to atopy and symptoms.","date":"1994","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8187030","citation_count":56,"is_preprint":false},{"pmid":"11842294","id":"PMC_11842294","title":"A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICAM-1) in children with asthma.","date":"2002","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11842294","citation_count":56,"is_preprint":false},{"pmid":"30442534","id":"PMC_30442534","title":"Bacterial Excretion of Cytoplasmic Proteins (ECP): Occurrence, Mechanism, and Function.","date":"2018","source":"Trends in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/30442534","citation_count":55,"is_preprint":false},{"pmid":"26009926","id":"PMC_26009926","title":"Excretion of cytoplasmic proteins (ECP) in Staphylococcus aureus.","date":"2015","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/26009926","citation_count":54,"is_preprint":false},{"pmid":"33203951","id":"PMC_33203951","title":"Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease.","date":"2020","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/33203951","citation_count":52,"is_preprint":false},{"pmid":"25596889","id":"PMC_25596889","title":"Excretion of cytosolic proteins (ECP) in bacteria.","date":"2014","source":"International journal of medical microbiology : IJMM","url":"https://pubmed.ncbi.nlm.nih.gov/25596889","citation_count":51,"is_preprint":false},{"pmid":"8288872","id":"PMC_8288872","title":"Measurement of eosinophil cationic protein (ECP) and eosinophil protein X/eosinophil derived neurotoxin (EPX/EDN). Time and temperature dependent spontaneous release in vitro demands standardized sample processing.","date":"1993","source":"Journal of immunological methods","url":"https://pubmed.ncbi.nlm.nih.gov/8288872","citation_count":51,"is_preprint":false},{"pmid":"10917466","id":"PMC_10917466","title":"Serum ECP and MPO are increased during exacerbations of chronic bronchitis with airway obstruction.","date":"2000","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/10917466","citation_count":49,"is_preprint":false},{"pmid":"19366593","id":"PMC_19366593","title":"Comparison of the membrane interaction mechanism of two antimicrobial RNases: RNase 3/ECP and RNase 7.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19366593","citation_count":49,"is_preprint":false},{"pmid":"9675876","id":"PMC_9675876","title":"Eosinophil cationic protein (ECP).","date":"1998","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9675876","citation_count":48,"is_preprint":false},{"pmid":"9761011","id":"PMC_9761011","title":"Induced sputum eosinophil cationic protein (ECP) measurement in asthma and chronic obstructive airway disease (COAD).","date":"1998","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9761011","citation_count":47,"is_preprint":false},{"pmid":"27527084","id":"PMC_27527084","title":"A Novel RNase 3/ECP Peptide for Pseudomonas aeruginosa Biofilm Eradication That Combines Antimicrobial, Lipopolysaccharide Binding, and Cell-Agglutinating Activities.","date":"2016","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/27527084","citation_count":47,"is_preprint":false},{"pmid":"11289329","id":"PMC_11289329","title":"Correlation between airway hyperresponsiveness and airway inflammation in a young adult population: eosinophil, ECP, and cytokine levels in induced sputum.","date":"2001","source":"Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11289329","citation_count":46,"is_preprint":false},{"pmid":"1685831","id":"PMC_1685831","title":"Eosinophilic cationic protein (ECP) in skin disorders.","date":"1991","source":"Acta dermato-venereologica","url":"https://pubmed.ncbi.nlm.nih.gov/1685831","citation_count":45,"is_preprint":false},{"pmid":"28684769","id":"PMC_28684769","title":"Eosinophil Cationic Protein (ECP), a predictive marker of bullous pemphigoid severity and outcome.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28684769","citation_count":44,"is_preprint":false},{"pmid":"31332045","id":"PMC_31332045","title":"Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD.","date":"2019","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/31332045","citation_count":43,"is_preprint":false},{"pmid":"17507019","id":"PMC_17507019","title":"The 434(G>C) polymorphism within the coding sequence of Eosinophil Cationic Protein (ECP) correlates with the natural course of Schistosoma mansoni infection.","date":"2007","source":"International journal for parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/17507019","citation_count":43,"is_preprint":false},{"pmid":"19692640","id":"PMC_19692640","title":"Eosinophil cationic protein (ECP) is processed during secretion.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19692640","citation_count":41,"is_preprint":false},{"pmid":"9556008","id":"PMC_9556008","title":"Serum eosinophil cationic protein (ECP) and eosinophil protein X (EPX) in childhood asthma: the influence of atopy.","date":"1998","source":"Pediatric pulmonology","url":"https://pubmed.ncbi.nlm.nih.gov/9556008","citation_count":41,"is_preprint":false},{"pmid":"10747267","id":"PMC_10747267","title":"Morbidity assessment in urinary schistosomiasis infection through ultrasonography and measurement of eosinophil cationic protein (ECP) in urine.","date":"2000","source":"Tropical medicine & international health : TM & IH","url":"https://pubmed.ncbi.nlm.nih.gov/10747267","citation_count":41,"is_preprint":false},{"pmid":"34633749","id":"PMC_34633749","title":"Targeting of SPCSV-RNase3 via CRISPR-Cas13 confers resistance against sweet potato virus disease.","date":"2021","source":"Molecular plant pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34633749","citation_count":38,"is_preprint":false},{"pmid":"1715291","id":"PMC_1715291","title":"Ribonuclease activity and substrate preference of human eosinophil cationic protein (ECP).","date":"1991","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/1715291","citation_count":38,"is_preprint":false},{"pmid":"10380774","id":"PMC_10380774","title":"Basophil histamine release, IgE, eosinophil counts, ECP, and EPX are related to the severity of symptoms in seasonal allergic rhinitis.","date":"1999","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/10380774","citation_count":37,"is_preprint":false},{"pmid":"16533031","id":"PMC_16533031","title":"Spider egg case core fibers: trimeric complexes assembled from TuSp1, ECP-1, and ECP-2.","date":"2006","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16533031","citation_count":36,"is_preprint":false},{"pmid":"20213669","id":"PMC_20213669","title":"Eosinophil cationic protein (ECP) can bind heparin and other glycosaminoglycans through its RNase active site.","date":"2011","source":"Journal of molecular recognition : JMR","url":"https://pubmed.ncbi.nlm.nih.gov/20213669","citation_count":35,"is_preprint":false},{"pmid":"28399677","id":"PMC_28399677","title":"Elevated serum levels of TNF-α, IL-8, and ECP can be involved in the development and progression of bronchial asthma.","date":"2017","source":"The Journal of asthma : official journal of the Association for the Care of Asthma","url":"https://pubmed.ncbi.nlm.nih.gov/28399677","citation_count":34,"is_preprint":false},{"pmid":"10336931","id":"PMC_10336931","title":"Eosinophilic myocarditis associated with dense deposits of eosinophil cationic protein (ECP) in endomyocardium with high serum ECP.","date":"1999","source":"Heart (British Cardiac Society)","url":"https://pubmed.ncbi.nlm.nih.gov/10336931","citation_count":34,"is_preprint":false},{"pmid":"9537775","id":"PMC_9537775","title":"Clinical utility of serum levels of eosinophil cationic protein (ECP) for monitoring and predicting clinical course in childhood asthma.","date":"1998","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9537775","citation_count":34,"is_preprint":false},{"pmid":"24837416","id":"PMC_24837416","title":"Updating ECP action mechanisms.","date":"2014","source":"Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis","url":"https://pubmed.ncbi.nlm.nih.gov/24837416","citation_count":33,"is_preprint":false},{"pmid":"10853846","id":"PMC_10853846","title":"Exhaled nitric oxide, serum ECP and airway responsiveness in mild asthmatic children.","date":"2000","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/10853846","citation_count":33,"is_preprint":false},{"pmid":"11530956","id":"PMC_11530956","title":"Eosinophil cationic protein (ECP) in saliva: a new marker of disease activity in bronchial asthma.","date":"2001","source":"Respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11530956","citation_count":32,"is_preprint":false},{"pmid":"8103623","id":"PMC_8103623","title":"Indirect assessment of eosinophiluria in urinary schistosomiasis using eosinophil cationic protein (ECP) and eosinophil protein X (EPX).","date":"1993","source":"Acta tropica","url":"https://pubmed.ncbi.nlm.nih.gov/8103623","citation_count":32,"is_preprint":false},{"pmid":"17362255","id":"PMC_17362255","title":"Eosinophil cationic protein (ECP) polymorphisms and association with asthma, s-ECP levels and related phenotypes.","date":"2007","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/17362255","citation_count":31,"is_preprint":false},{"pmid":"27442906","id":"PMC_27442906","title":"Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee.","date":"2016","source":"Journal of clinical apheresis","url":"https://pubmed.ncbi.nlm.nih.gov/27442906","citation_count":31,"is_preprint":false},{"pmid":"7539247","id":"PMC_7539247","title":"Comparative immunoreactivity of the eosinophil constituents MBP and ECP in different types of urticaria.","date":"1995","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/7539247","citation_count":31,"is_preprint":false},{"pmid":"25320086","id":"PMC_25320086","title":"Escherichia coli common pilus (ECP) targets arabinosyl residues in plant cell walls to mediate adhesion to fresh produce plants.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25320086","citation_count":30,"is_preprint":false},{"pmid":"10400487","id":"PMC_10400487","title":"Expression of ICAM-1 on conjunctival epithelium and ECP in tears and serum from children with allergic conjunctivitis.","date":"1999","source":"Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10400487","citation_count":29,"is_preprint":false},{"pmid":"22797761","id":"PMC_22797761","title":"Transcriptional regulation of the ecp operon by EcpR, IHF, and H-NS in attaching and effacing Escherichia coli.","date":"2012","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/22797761","citation_count":29,"is_preprint":false},{"pmid":"25653504","id":"PMC_25653504","title":"Systematic review and meta-analysis of prospective studies for ECP treatment in patients with steroid-refractory acute GVHD.","date":"2015","source":"Patient preference and adherence","url":"https://pubmed.ncbi.nlm.nih.gov/25653504","citation_count":29,"is_preprint":false},{"pmid":"8172362","id":"PMC_8172362","title":"Twenty-four-hour time course of eosinophil granule proteins ECP and EPX during bronchial allergen challenges in serum of asthmatic children.","date":"1994","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/8172362","citation_count":28,"is_preprint":false},{"pmid":"32082329","id":"PMC_32082329","title":"Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD).","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32082329","citation_count":27,"is_preprint":false},{"pmid":"8874658","id":"PMC_8874658","title":"Serum eosinophil cationic protein (ECP) as a marker of disease activity and treatment efficacy in seasonal asthma.","date":"1996","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/8874658","citation_count":27,"is_preprint":false},{"pmid":"32447349","id":"PMC_32447349","title":"Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level.","date":"2020","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/32447349","citation_count":27,"is_preprint":false},{"pmid":"10836321","id":"PMC_10836321","title":"Allergen challenge-induced acute exudation of IL-8, ECP and alpha2-macroglobulin in human rhinovirus-induced common colds.","date":"1999","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/10836321","citation_count":27,"is_preprint":false},{"pmid":"22460069","id":"PMC_22460069","title":"RAGE processing in chronic airway conditions: involvement of Staphylococcus aureus and ECP.","date":"2012","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22460069","citation_count":26,"is_preprint":false},{"pmid":"20301140","id":"PMC_20301140","title":"The use of fluid boluses to safely perform extracorporeal photopheresis (ECP) in low-weight children: a novel procedure.","date":"2010","source":"Journal of clinical apheresis","url":"https://pubmed.ncbi.nlm.nih.gov/20301140","citation_count":26,"is_preprint":false},{"pmid":"8060919","id":"PMC_8060919","title":"Serum soluble IL-2 receptor (sIL-2R) and eosinophil cationic protein (ECP) levels in atopic dermatitis.","date":"1994","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/8060919","citation_count":25,"is_preprint":false},{"pmid":"29575114","id":"PMC_29575114","title":"American council on ECP (ACE): Why now?","date":"2018","source":"Journal of clinical apheresis","url":"https://pubmed.ncbi.nlm.nih.gov/29575114","citation_count":25,"is_preprint":false},{"pmid":"9279689","id":"PMC_9279689","title":"Eosinophil cationic protein (ECP) level and its correlation with eosinophil number or IgE level of peripheral blood in patients with various skin diseases.","date":"1997","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/9279689","citation_count":25,"is_preprint":false},{"pmid":"10524211","id":"PMC_10524211","title":"Isolation, molecular characterization, and tissue-specific expression of ECP-51 and ECP-54 (TIP49), two homologous, interacting erythroid cytosolic proteins.","date":"1999","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/10524211","citation_count":25,"is_preprint":false},{"pmid":"31908057","id":"PMC_31908057","title":"Extracorporeal photopheresis for graft-vs-host disease: A literature review and treatment guidelines proposed by the Nordic ECP Quality Group.","date":"2020","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/31908057","citation_count":25,"is_preprint":false},{"pmid":"9179426","id":"PMC_9179426","title":"The use of serum eosinophil cationic protein (ECP) in the management of steroid therapy in chronic asthma.","date":"1997","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9179426","citation_count":25,"is_preprint":false},{"pmid":"9237061","id":"PMC_9237061","title":"Chemoprevention of metachronous adenomas of the large bowel: design and interim results of a randomized trial of calcium and fibre. ECP Colon Group.","date":"1997","source":"European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)","url":"https://pubmed.ncbi.nlm.nih.gov/9237061","citation_count":25,"is_preprint":false},{"pmid":"22275342","id":"PMC_22275342","title":"IgE and eosinophil cationic protein (ECP) as markers of severity in the diagnosis of atopic keratoconjunctivitis.","date":"2012","source":"The British journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/22275342","citation_count":23,"is_preprint":false},{"pmid":"10424438","id":"PMC_10424438","title":"Differentiation of a human eosinophilic leukemic cell line, EoL-1: characterization by the expression of cytokine receptors, adhesion molecules, CD95 and eosinophilic cationic protein (ECP).","date":"1999","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/10424438","citation_count":23,"is_preprint":false},{"pmid":"21679745","id":"PMC_21679745","title":"Effect of eosinophil cationic protein (ECP) on Hodgkin lymphoma cell lines.","date":"2011","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/21679745","citation_count":22,"is_preprint":false},{"pmid":"8109700","id":"PMC_8109700","title":"Comparison of sputum-ECP levels in bronchial asthma and chronic bronchitis.","date":"1993","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/8109700","citation_count":22,"is_preprint":false},{"pmid":"8765229","id":"PMC_8765229","title":"Purification and characterization of the proteinase ECP 32 from Escherichia coli A2 strain.","date":"1996","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/8765229","citation_count":22,"is_preprint":false},{"pmid":"11862965","id":"PMC_11862965","title":"The inflammatory marker serum eosinophil cationic protein (ECP) compared with PEF as a tool to decide inhaled corticosteroid dose in asthmatic patients.","date":"2002","source":"Respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11862965","citation_count":22,"is_preprint":false},{"pmid":"19542456","id":"PMC_19542456","title":"The coding ECP 434(G>C) gene polymorphism determines the cytotoxicity of ECP but has minor effects on fibroblast-mediated gel contraction and no effect on RNase activity.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19542456","citation_count":21,"is_preprint":false},{"pmid":"12417023","id":"PMC_12417023","title":"RNase 3 (ECP) is an extraordinarily stable protein among human pancreatic-type RNases.","date":"2002","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12417023","citation_count":21,"is_preprint":false},{"pmid":"11263991","id":"PMC_11263991","title":"SNARE proteins are critical for regulated exocytosis of ECP from human eosinophils.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11263991","citation_count":21,"is_preprint":false},{"pmid":"24768429","id":"PMC_24768429","title":"ECP and solid organ transplantation.","date":"2014","source":"Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis","url":"https://pubmed.ncbi.nlm.nih.gov/24768429","citation_count":19,"is_preprint":false},{"pmid":"11745972","id":"PMC_11745972","title":"Human muscle protein degradation in vitro by eosinophil cationic protein (ECP).","date":"2001","source":"Muscle & nerve","url":"https://pubmed.ncbi.nlm.nih.gov/11745972","citation_count":19,"is_preprint":false},{"pmid":"12883827","id":"PMC_12883827","title":"ECP-treated lymphocytes of chronic graft-versus-host disease patients undergo apoptosis which involves both the Fas/FasL system and the Bcl-2 protein family.","date":"2003","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/12883827","citation_count":19,"is_preprint":false},{"pmid":"9179427","id":"PMC_9179427","title":"Asthma, bronchial hyperreactivity and mediator release in children with birch pollinosis. ECP and EPX levels are not related to bronchial hyperreactivity.","date":"1997","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9179427","citation_count":19,"is_preprint":false},{"pmid":"22216286","id":"PMC_22216286","title":"Polymorphisms in the RNASE3 gene are associated with susceptibility to cerebral malaria in Ghanaian children.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22216286","citation_count":18,"is_preprint":false},{"pmid":"29763807","id":"PMC_29763807","title":"Positional scanning library applied to the human eosinophil cationic protein/RNase3 N-terminus reveals novel and potent anti-biofilm peptides.","date":"2018","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29763807","citation_count":18,"is_preprint":false},{"pmid":"11699410","id":"PMC_11699410","title":"The serum levels of eosinophil cationic protein (ECP) are related to the infiltration of eosinophils in the tumours of patients with Hodgkin's disease.","date":"2001","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/11699410","citation_count":18,"is_preprint":false},{"pmid":"27391019","id":"PMC_27391019","title":"Viral RNase3 Co-Localizes and Interacts with the Antiviral Defense Protein SGS3 in Plant Cells.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27391019","citation_count":17,"is_preprint":false},{"pmid":"16434694","id":"PMC_16434694","title":"A (G->C) transversion in the 3' UTR of the human ECP (eosinophil cationic protein) gene correlates to the cellular content of ECP.","date":"2006","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/16434694","citation_count":17,"is_preprint":false},{"pmid":"11206383","id":"PMC_11206383","title":"DFT/ECP study of C-H activation by (PCP)Ir and (PCP)Ir(H)2(PCP=eta3-1,3-C6H3(CH2PR2)2). Enthalpies and free energies of associative and dissociative pathways.","date":"2001","source":"Journal of chemical information and computer sciences","url":"https://pubmed.ncbi.nlm.nih.gov/11206383","citation_count":17,"is_preprint":false},{"pmid":"10843424","id":"PMC_10843424","title":"Measurements of ECP in serum and the impact of plasma coagulation.","date":"2000","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/10843424","citation_count":16,"is_preprint":false},{"pmid":"6842259","id":"PMC_6842259","title":"Eosinophil cationic protein (ECP) in the cerebrospinal fluid.","date":"1983","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/6842259","citation_count":16,"is_preprint":false},{"pmid":"7751092","id":"PMC_7751092","title":"Serum eosinophil cationic protein (ECP) in bullous pemphigoid.","date":"1995","source":"International journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/7751092","citation_count":16,"is_preprint":false},{"pmid":"8050551","id":"PMC_8050551","title":"Effects of PAF, FMLP and opsonized zymosan on the release of ECP, elastase and superoxide from human granulocytes.","date":"1994","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/8050551","citation_count":16,"is_preprint":false},{"pmid":"25220858","id":"PMC_25220858","title":"Biological quality control for extracorporeal photochemotherapy: Assessing mononuclear cell apoptosis levels in ECP bags of chronic GvHD patients.","date":"2014","source":"Journal of clinical apheresis","url":"https://pubmed.ncbi.nlm.nih.gov/25220858","citation_count":16,"is_preprint":false},{"pmid":"8871737","id":"PMC_8871737","title":"Serum ECP levels in asthmatic patients: comparison with other follow-up parameters.","date":"1996","source":"Allergy and asthma proceedings","url":"https://pubmed.ncbi.nlm.nih.gov/8871737","citation_count":15,"is_preprint":false},{"pmid":"17609808","id":"PMC_17609808","title":"ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.","date":"2007","source":"Skin therapy letter","url":"https://pubmed.ncbi.nlm.nih.gov/17609808","citation_count":14,"is_preprint":false},{"pmid":"8984917","id":"PMC_8984917","title":"Effects of inhaled steroid treatment on serum eosinophilic cationic protein (ECP) and low affinity receptor for IgE (Fc epsilon RII/sCD23) in childhood bronchial asthma.","date":"1996","source":"Archives of disease in childhood","url":"https://pubmed.ncbi.nlm.nih.gov/8984917","citation_count":14,"is_preprint":false},{"pmid":"15171821","id":"PMC_15171821","title":"Do tryptase, ECP and specific IgE measurement by nasal incubation increase the specific nasal provocation test sensitivity?","date":"2004","source":"International journal of immunopathology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15171821","citation_count":14,"is_preprint":false},{"pmid":"9578914","id":"PMC_9578914","title":"Serum eosinophil cationic protein (ECP) levels in patients with seasonal allergic rhinitis and allergic asthma.","date":"1998","source":"Allergy and asthma proceedings","url":"https://pubmed.ncbi.nlm.nih.gov/9578914","citation_count":13,"is_preprint":false},{"pmid":"7982122","id":"PMC_7982122","title":"Eosinophil cationic protein (ECP), histamine and tryptase in peripheral blood before and during inhalation challenge with toluene diisocyanate (TDI) in sensitized subjects.","date":"1994","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7982122","citation_count":13,"is_preprint":false},{"pmid":"10604557","id":"PMC_10604557","title":"Serum eosinophil cationic protein (ECP): reference values in healthy nonatopic children.","date":"1999","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/10604557","citation_count":13,"is_preprint":false},{"pmid":"29867850","id":"PMC_29867850","title":"Distribution of Major Pilin Subunit Genes Among Atypical Enteropathogenic Escherichia coli and Influence of Growth Media on Expression of the ecp Operon.","date":"2018","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/29867850","citation_count":13,"is_preprint":false},{"pmid":"20534163","id":"PMC_20534163","title":"Associations of ECP (eosinophil cationic protein)-gene polymorphisms to allergy, asthma, smoke habits and lung function in two Estonian and Swedish sub cohorts of the ECRHS II study.","date":"2010","source":"BMC pulmonary medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20534163","citation_count":13,"is_preprint":false},{"pmid":"16573548","id":"PMC_16573548","title":"The down-regulation of IL1alpha and IL6, in monocytes exposed to extracorporeal photopheresis (ECP)-treated lymphocytes, is not dependent on lymphocyte phosphatidylserine externalization.","date":"2006","source":"Transplant international : official journal of the European Society for Organ Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/16573548","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53400,"output_tokens":3962,"usd":0.109815,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11742,"output_tokens":4003,"usd":0.079393,"stage2_stop_reason":"end_turn"},"total_usd":0.189208,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1986,\n      \"finding\": \"ECP (RNASE3) possesses ribonuclease activity; purified ECP resolved into subfractions by ion exchange chromatography all showed RNase activity, though ~125-fold lower than EPX/EDN. ECP may exert cytotoxic effects by degrading mRNA after internalization.\",\n      \"method\": \"Ion exchange chromatography of purified ECP, RNase activity assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct enzymatic assay on purified protein, replicated across multiple subfractions, consistent with subsequent substrate-preference studies\",\n      \"pmids\": [\"3768000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"ECP and EPX dose-dependently suppressed lymphocyte proliferation (PHA-blasts and MLR-blasts) in vitro; the effect was irreversible and not due to cytotoxic cell damage, suggesting a regulatory immunosuppressive role for eosinophil-derived proteins.\",\n      \"method\": \"In vitro lymphocyte proliferation assay with purified ECP/EPX, 3H-thymidine incorporation\",\n      \"journal\": \"Immunobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct in vitro functional assay on purified protein, single lab, no mechanistic pathway placement beyond the observed phenotype\",\n      \"pmids\": [\"2940166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"ECP's RNase activity shows substrate preference for single-stranded RNA (poly(U) > poly(C) >> poly(A)); double-stranded substrates and defined dinucleoside phosphate substrates showed negligible hydrolysis, linking ECP ribonucleolytic activity to 'non-secretory' liver-type enzymes rather than pancreatic-type RNases.\",\n      \"method\": \"In vitro RNase activity assay with synthetic polyribonucleotide substrates, dinucleoside phosphates, and cyclic phosphates\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct substrate-preference enzymatic assay with multiple substrates on purified protein, single lab but multiple orthogonal substrate tests\",\n      \"pmids\": [\"1715291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Optimal expression of the ECP (RNS3) gene is mediated by an intronic enhancer element containing an NFAT-1 consensus binding sequence (5'-GGAGAG-3'); nuclear proteins from HL-60 cells bind this site and disruption reduces reporter gene activity to background. A single nucleotide difference from the EDN intronic NFAT-1 site further enhanced ECP reporter activity. No supershift was detected with anti-NFAT-1 antiserum, suggesting a protein other than NFAT-1 may act at this site.\",\n      \"method\": \"Reporter gene assay, gel shift (EMSA) with nuclear proteins from HL-60 cells, site-directed mutagenesis of consensus sequence\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay plus EMSA with mutagenesis, single lab; identity of binding protein unresolved (negative supershift result for NFAT-1)\",\n      \"pmids\": [\"8999843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"SNARE proteins (VAMP-2, syntaxin 4, SNAP-23/SNAP-25) are present in human eosinophils and are required for regulated ECP exocytosis; tetanus toxin pretreatment, which cleaved VAMP-2, significantly inhibited both IgE receptor- and phorbol ester-mediated ECP release from streptolysin-O-permeabilized eosinophils.\",\n      \"method\": \"Immunoblotting, subcellular fractionation, immunocytochemistry, RT-PCR, tetanus toxin cleavage of VAMP-2, exocytosis assay in permeabilized eosinophils\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (fractionation, immunocytochemistry, functional inhibition via toxin), single lab; mechanistic pathway placement clear\",\n      \"pmids\": [\"11263991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Human RNase 3 (ECP) is extraordinarily stable compared with other human pancreatic-type RNases (RNases 1–5) and bovine RNase A, with a ΔΔG of >25 kJ/mol in guanidinium chloride-induced unfolding experiments; this exceptional stability may enable ECP to accumulate in the cytosol after endocytosis to levels exceeding those of the RNase inhibitor, contributing to its unique cytotoxic properties.\",\n      \"method\": \"Guanidinium chloride-induced denaturation, two-state unfolding analysis, comparison across five human RNases and RNase A\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — rigorous biophysical assay, but single lab and mechanistic link to cytotoxicity is inferential from stability data\",\n      \"pmids\": [\"12417023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ECP (RNase 3) triggers vesicle aggregation as the primary membrane interaction event, whereas RNase 7 induces leakage before aggregation; RNase 3 membrane interaction involves aggregation of phospholipid vesicles followed by leakage, distinct from RNase 7's mechanism, as shown by confocal microscopy with GUVs, liposome content-release assay, electron microscopy of lipid/protein aggregates, and FTIR of secondary structure in lipid microenvironment.\",\n      \"method\": \"Phospholipid vesicle model membranes, confocal microscopy (giant unilamellar vesicles), liposome content-release (leakage) assay, transmission electron microscopy, FTIR spectroscopy\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal biophysical methods (confocal, TEM, FTIR, leakage assay), single lab, defines specific membrane interaction mechanism\",\n      \"pmids\": [\"19366593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ECP secretion from activated eosinophils involves post-translational processing: unstimulated eosinophils contain 10 major ECP variants (16.1–17.7 kDa); particle stimulation selectively secretes 16.1 and 16.3 kDa variants (the cytotoxic species), while cytokine stimulation produces a different secretion profile. Modifications of secreted ECP are partly explained by differences in N-linked glycosylations.\",\n      \"method\": \"SELDI-TOF mass spectrometry, affinity capture assay, fluoroenzyme immunoassay, eosinophil stimulation with particles/cytokines\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — SELDI-TOF with functional stimulation conditions, single lab, two orthogonal analytical methods; glycosylation differences identified but full characterization incomplete\",\n      \"pmids\": [\"19692640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The arg97thr amino acid substitution encoded by the ECP 434(G>C) polymorphism dramatically abolishes cytotoxic capacity of native ECP toward NCI-H69 small-cell lung cancer cells, but does not affect RNase activity and only minimally affects fibroblast-mediated collagen gel contraction, demonstrating dissociation between different biological activities of ECP.\",\n      \"method\": \"Native ECP(97arg) and ECP(97thr) variants extracted from blood donors, fluorometric microculture cytotoxicity assay, RNase activity assay, fibroblast collagen gel contraction assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — first-ever native protein variant comparison with three orthogonal functional assays (cytotoxicity, RNase, gel contraction), single lab but multiple rigorous endpoints\",\n      \"pmids\": [\"19542456\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ECP heparin-binding affinity is dependent on its RNase catalytic site: heparin and other negatively charged glycosaminoglycans (GAGs) block ECP enzymatic activity, and molecular modeling identified catalytic and substrate-binding site residues as contributors to GAG interaction, explaining ECP binding to the eukaryote glycocalyx and bacteria cell wall carbohydrates.\",\n      \"method\": \"Enzymatic activity inhibition assay with heparin/GAGs, molecular modeling\",\n      \"journal\": \"Journal of molecular recognition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct enzymatic inhibition assay plus computational modeling, single lab; mechanistic link to antimicrobial action is partially inferential\",\n      \"pmids\": [\"20213669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ECP degrades myofibrillar proteins (myosin heavy chain, α-actinin) and membrane-associated cytoskeletal proteins (dystrophin, spectrin) in vitro in a dose-dependent, pH 7.0-optimal manner; soluble sarcoplasmic proteins were not degraded. Degradation was not inhibited by heparin or protease inhibitors (leupeptin, E-64, pepstatin A).\",\n      \"method\": \"In vitro incubation of muscle protein fractions with purified ECP, SDS-PAGE, immunoblotting, quantitative MHC degradation assay\",\n      \"journal\": \"Muscle & nerve\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct in vitro proteolytic assay on purified protein with defined substrates and inhibitor controls, single lab\",\n      \"pmids\": [\"11745972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ECP is implicated in the breakdown of free soluble RAGE (sRAGE) in sinonasal tissue; ex vivo human sinonasal tissue stimulation with ECP reduced sRAGE levels, while S. aureus induced sRAGE release from tissue.\",\n      \"method\": \"Ex vivo sinonasal tissue stimulation assay, quantitative protein measurement (ELISA/immunoassay) for sRAGE, mRAGE, ECP, IL-5\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single ex vivo stimulation assay, single lab; mechanism of sRAGE breakdown not characterized at molecular level\",\n      \"pmids\": [\"22460069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"An ECP-derived peptide (RN3(5-17P22-36)) achieves biofilm eradication of Pseudomonas aeruginosa through combined LPS-binding, bacterial cell agglutination, and membrane destabilization activities; biofilm eradication by the parental ECP protein is not dependent on RNase catalytic activity, as demonstrated with an active site-defective mutant.\",\n      \"method\": \"Active site-defective mutant biofilm eradication assay, LPS-binding assay, bacterial agglutination assay, bactericidal activity assay against P. aeruginosa PAO1\",\n      \"journal\": \"Antimicrobial agents and chemotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — active-site mutant experiment directly dissociates RNase activity from biofilm eradication; multiple functional readouts, single lab\",\n      \"pmids\": [\"27527084\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"A G→C transversion at position 562 in the 3' UTR of the ECP (RNASE3) gene is associated with significantly lower cellular ECP content in eosinophils (ECP562GC: 4.6 µg/10^6 cells; GG: 6.0 µg/10^6 cells; CC: 3.2 µg/10^6 cells), suggesting this UTR polymorphism regulates ECP production/storage at a post-transcriptional level.\",\n      \"method\": \"Gene sequencing, ECP cellular content measurement by RIA in donors stratified by genotype\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct genotype-to-protein-level correlation with quantitative cellular measurement across n=163 subjects; single lab, no mechanistic dissection of UTR function\",\n      \"pmids\": [\"16434694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"EoL-1 eosinophilic leukemic cells differentiated by dibutyryl cAMP upregulate ECP mRNA expression and increase both ECP synthesis and secretion into supernatant, establishing that ECP expression is regulated at the transcriptional level during eosinophil differentiation.\",\n      \"method\": \"RT-PCR for ECP mRNA, fluorescence enzyme immunoassay for ECP protein in cells and supernatant, dbcAMP differentiation model\",\n      \"journal\": \"Immunology letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single cell-line model, single lab, no mechanistic dissection of transcriptional pathway\",\n      \"pmids\": [\"10424438\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RNASE3 (ECP) is a highly basic eosinophil granule ribonuclease (with low but measurable RNase activity preferring single-stranded poly(U)/poly(C) substrates) that is secreted via a SNARE-dependent (VAMP-2/syntaxin-4) exocytosis mechanism with concomitant N-glycosylation-dependent processing into cytotoxic variants; its cytotoxicity is mediated primarily through membrane aggregation and destabilization rather than RNase activity, its heparin/GAG-binding affinity is mediated through the RNase catalytic site, its gene expression is regulated by an intronic NFAT-1-like enhancer element, and the arg97thr (434G>C) coding polymorphism dissociates cytotoxic activity from RNase activity without affecting the latter.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RNASE3 (eosinophil cationic protein, ECP) is a highly basic eosinophil granule ribonuclease whose dominant biological function is cytotoxic and antimicrobial membrane disruption rather than RNA catalysis [#6, #8]. It possesses measurable but weak ribonuclease activity (~125-fold lower than EDN/EPX) with a marked preference for single-stranded substrates, poly(U) > poly(C) >> poly(A), aligning it with non-secretory liver-type rather than pancreatic-type RNases [#0, #2]. The protein engages membranes primarily by aggregating phospholipid vesicles followed by leakage, a mechanism distinct from RNase 7 [#6], and its cytotoxicity is genetically separable from catalysis: the arg97thr (434G>C) substitution abolishes cytotoxicity toward target cells while leaving RNase activity intact [#8]. Likewise, biofilm eradication of Pseudomonas aeruginosa proceeds through LPS binding, bacterial agglutination, and membrane destabilization independent of the catalytic site [#12], while heparin/glycosaminoglycan binding — which underlies engagement of the glycocalyx and bacterial cell-wall carbohydrates — is itself mediated through the RNase catalytic and substrate-binding residues [#9]. ECP is stored in eosinophil granules and released by SNARE-dependent regulated exocytosis requiring VAMP-2 and syntaxin-4, with stimulus-selective secretion of N-glycosylation-defined cytotoxic variants [#4, #7]. Its expression is controlled both transcriptionally via an intronic NFAT-1-like enhancer element [#3] and post-transcriptionally via a 3'UTR polymorphism that sets cellular ECP content [#13].\",\n  \"teleology\": [\n    {\n      \"year\": 1986,\n      \"claim\": \"Established that ECP is an enzymatically active ribonuclease, framing it as a member of the RNase superfamily and raising the question of whether RNA degradation underlies its biological effects.\",\n      \"evidence\": \"Ion exchange chromatography of purified ECP with RNase activity assays across subfractions\",\n      \"pmids\": [\"3768000\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not determine whether RNase activity drives cytotoxicity\", \"Activity ~125-fold lower than EDN/EPX, leaving functional relevance unclear\"]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Showed ECP has an immunoregulatory dimension, irreversibly suppressing lymphocyte proliferation independent of overt cell damage.\",\n      \"evidence\": \"In vitro lymphocyte proliferation assay (PHA/MLR blasts) with purified ECP, 3H-thymidine incorporation\",\n      \"pmids\": [\"2940166\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No molecular pathway or receptor identified\", \"Mechanism of irreversible suppression not defined\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Defined the substrate preference of ECP (single-stranded poly(U)>poly(C)>>poly(A)), placing it with non-secretory liver-type rather than pancreatic-type RNases.\",\n      \"evidence\": \"In vitro RNase assays with synthetic polyribonucleotides, dinucleoside phosphates, and cyclic phosphates\",\n      \"pmids\": [\"1715291\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological RNA substrate in vivo not identified\", \"Does not connect catalysis to cellular function\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identified an intronic NFAT-1-like enhancer driving optimal ECP gene expression, addressing how the gene is transcriptionally controlled.\",\n      \"evidence\": \"Reporter assays, EMSA with HL-60 nuclear extracts, site-directed mutagenesis\",\n      \"pmids\": [\"8999843\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the binding protein unresolved (anti-NFAT-1 supershift negative)\", \"Upstream signaling that activates the enhancer unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Linked ECP expression to eosinophil differentiation, showing transcriptional upregulation upon dbcAMP-induced maturation.\",\n      \"evidence\": \"RT-PCR and enzyme immunoassay in dbcAMP-differentiated EoL-1 leukemic cells\",\n      \"pmids\": [\"10424438\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single cell-line model, not validated in primary eosinophils\", \"No transcriptional pathway dissected\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Resolved the secretion mechanism, establishing that regulated ECP exocytosis is SNARE-dependent and requires VAMP-2.\",\n      \"evidence\": \"Immunoblotting, fractionation, immunocytochemistry, tetanus-toxin cleavage of VAMP-2, exocytosis assay in permeabilized eosinophils\",\n      \"pmids\": [\"11263991\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full SNARE complex stoichiometry not defined\", \"Link between stimulus type and SNARE selection unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated ECP proteolytic degradation of myofibrillar and membrane cytoskeletal proteins, expanding its activities beyond RNA catalysis.\",\n      \"evidence\": \"In vitro incubation of muscle protein fractions with purified ECP, SDS-PAGE, immunoblot, with protease-inhibitor controls\",\n      \"pmids\": [\"11745972\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Catalytic basis of proteolysis (not blocked by standard protease inhibitors) unexplained\", \"In vivo relevance to tissue damage not established\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed ECP is exceptionally thermodynamically stable, providing a biophysical rationale for cytosolic persistence above RNase inhibitor levels.\",\n      \"evidence\": \"Guanidinium chloride denaturation and two-state unfolding analysis across human RNases and RNase A\",\n      \"pmids\": [\"12417023\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cytotoxicity link is inferential from stability\", \"Cytosolic accumulation not directly measured\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined the primary membrane interaction mechanism as vesicle aggregation followed by leakage, distinguishing ECP from RNase 7.\",\n      \"evidence\": \"GUV confocal microscopy, liposome content-release assay, TEM, FTIR with model membranes\",\n      \"pmids\": [\"19366593\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Membrane target specificity on living cells not defined\", \"Structural determinants of aggregation not mapped\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed stimulus-selective secretion of N-glycosylation-defined ECP variants, identifying the cytotoxic 16.1/16.3 kDa species.\",\n      \"evidence\": \"SELDI-TOF MS, affinity capture, fluoroenzyme immunoassay after particle vs cytokine stimulation\",\n      \"pmids\": [\"19692640\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Glycan structures only partly characterized\", \"Enzymes generating the variants not identified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Genetically dissociated cytotoxicity from RNase activity, showing arg97thr abolishes cytotoxicity without affecting catalysis.\",\n      \"evidence\": \"Native ECP(97arg/97thr) variants from donors tested by cytotoxicity, RNase, and collagen gel contraction assays\",\n      \"pmids\": [\"19542456\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of how residue 97 controls cytotoxicity unknown\", \"Target-cell receptor/interaction not identified\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Mapped heparin/GAG binding to the RNase catalytic site, explaining glycocalyx and bacterial cell-wall engagement.\",\n      \"evidence\": \"Enzymatic inhibition assays with heparin/GAGs plus molecular modeling\",\n      \"pmids\": [\"20213669\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Modeling not validated by structure of GAG complex\", \"Antimicrobial link partly inferential\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Implicated ECP in degradation of soluble RAGE in sinonasal tissue, suggesting a role in modulating innate immune signaling substrates.\",\n      \"evidence\": \"Ex vivo human sinonasal tissue stimulation with ECP and quantitation of sRAGE/mRAGE\",\n      \"pmids\": [\"22460069\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single ex vivo assay, not independently confirmed\", \"Molecular mechanism of sRAGE breakdown uncharacterized\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established that antibacterial biofilm eradication is independent of RNase activity, mediated by LPS binding, agglutination, and membrane destabilization.\",\n      \"evidence\": \"Active-site-defective mutant biofilm assay, LPS-binding, agglutination, and bactericidal assays against P. aeruginosa\",\n      \"pmids\": [\"27527084\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Bacterial membrane target specificity not defined\", \"Relevance of peptide derivative vs full protein in vivo unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How residue 97 and N-glycosylation status structurally control the membrane-aggregation cytotoxic mechanism, and what cellular receptors or targets mediate ECP cytotoxicity and immunomodulation in vivo, remain open.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of ECP bound to membrane or target\", \"No identified cell-surface receptor for cytotoxicity\", \"In vivo physiological substrates undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"GO:0090729\", \"supporting_discovery_ids\": [6, 8]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [6, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [4, 7]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [4, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 4, 12]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [4, 7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"VAMP2\", \"STX4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}